AR098614A1 - Compuesto para el tratamiento de hipoglicemia severa - Google Patents

Compuesto para el tratamiento de hipoglicemia severa

Info

Publication number
AR098614A1
AR098614A1 ARP140104512A ARP140104512A AR098614A1 AR 098614 A1 AR098614 A1 AR 098614A1 AR P140104512 A ARP140104512 A AR P140104512A AR P140104512 A ARP140104512 A AR P140104512A AR 098614 A1 AR098614 A1 AR 098614A1
Authority
AR
Argentina
Prior art keywords
treatment
compound
severe hypoglycemia
hypoglycemia
severe
Prior art date
Application number
ARP140104512A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR098614A1 publication Critical patent/AR098614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Removal Of Specific Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente se refiere a un compuesto útil en el tratamiento de hipoglicemia. Composición farmacéutica.
ARP140104512A 2013-12-18 2014-12-04 Compuesto para el tratamiento de hipoglicemia severa AR098614A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361917597P 2013-12-18 2013-12-18

Publications (1)

Publication Number Publication Date
AR098614A1 true AR098614A1 (es) 2016-06-01

Family

ID=52278802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104512A AR098614A1 (es) 2013-12-18 2014-12-04 Compuesto para el tratamiento de hipoglicemia severa

Country Status (27)

Country Link
US (1) US9695225B2 (es)
EP (1) EP3083668A1 (es)
JP (1) JP2017509584A (es)
KR (1) KR20160075825A (es)
CN (1) CN105814076A (es)
AP (1) AP2016009242A0 (es)
AR (1) AR098614A1 (es)
AU (1) AU2014366424B2 (es)
BR (1) BR112016012067A2 (es)
CA (1) CA2928985A1 (es)
CL (1) CL2016001472A1 (es)
CR (1) CR20160226A (es)
DO (1) DOP2016000096A (es)
EA (1) EA201690914A1 (es)
EC (1) ECSP16024798A (es)
GT (1) GT201600117A (es)
HK (1) HK1224304A1 (es)
IL (1) IL245400A0 (es)
MA (1) MA39109B1 (es)
MX (1) MX2016007982A (es)
NZ (1) NZ719463A (es)
PE (1) PE20160848A1 (es)
PH (1) PH12016501182A1 (es)
SG (1) SG11201604154SA (es)
TN (1) TN2016000181A1 (es)
TW (1) TW201609127A (es)
WO (1) WO2015094875A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN113396156A (zh) 2019-02-05 2021-09-14 伊莱利利公司 胰高血糖素类似物激动剂及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2010012695A (es) * 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
US20120148586A1 (en) * 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2568993A4 (en) * 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
DK2718318T3 (en) * 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
JP6396211B2 (ja) 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
AR091477A1 (es) * 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip

Also Published As

Publication number Publication date
US20160311881A1 (en) 2016-10-27
SG11201604154SA (en) 2016-07-28
DOP2016000096A (es) 2016-08-15
GT201600117A (es) 2017-07-06
CA2928985A1 (en) 2015-06-25
WO2015094875A1 (en) 2015-06-25
MA39109B1 (fr) 2018-04-30
EP3083668A1 (en) 2016-10-26
NZ719463A (en) 2017-09-29
AP2016009242A0 (en) 2016-06-30
BR112016012067A2 (pt) 2017-09-26
EA201690914A1 (ru) 2016-09-30
MX2016007982A (es) 2016-09-09
AU2014366424A1 (en) 2016-05-19
AU2014366424B2 (en) 2017-02-16
KR20160075825A (ko) 2016-06-29
US9695225B2 (en) 2017-07-04
CN105814076A (zh) 2016-07-27
IL245400A0 (en) 2016-06-30
ECSP16024798A (es) 2017-05-31
CR20160226A (es) 2016-07-12
PE20160848A1 (es) 2016-09-10
TN2016000181A1 (en) 2017-10-06
JP2017509584A (ja) 2017-04-06
CL2016001472A1 (es) 2017-03-10
MA39109A1 (fr) 2017-09-29
PH12016501182A1 (en) 2016-07-25
TW201609127A (zh) 2016-03-16
HK1224304A1 (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
CO6771428A2 (es) Composición efervescente en forma sólida para uso en aplicaciones vaginales para el tratamiento de infecciones vaginales
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
UY36075A (es) Derivados de tubulisina
GT201500247A (es) Imidazopiridazinas sustituidas
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
DOP2016000142A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
GT201600117A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
CL2016000171A1 (es) Formulación de metaxalona.
ZA201509091B (en) Antivirally effective pharmaceutical composition
BR112015023730A2 (pt) uso de sedoeptulose como suplemento nutricional
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
ES1078913Y (es) Dispositivo de avance mandibular combinado con depresion lingual para el tratamiento del ronquido.
TH127247B (th) องค์ประกอบสำหรับการปรับปรุงสภาพของผิวหนัง

Legal Events

Date Code Title Description
FB Suspension of granting procedure